These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 17359512)

  • 1. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
    Vincenti F; Friman S; Scheuermann E; Rostaing L; Jenssen T; Campistol JM; Uchida K; Pescovitz MD; Marchetti P; Tuncer M; Citterio F; Wiecek A; Chadban S; El-Shahawy M; Budde K; Goto N;
    Am J Transplant; 2007 Jun; 7(6):1506-14. PubMed ID: 17359512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
    Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
    Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
    Vincenti F; Tuncer M; Castagneto M; Klinger M; Friman S; Scheuermann EH; Wiecek A; Russ GR; Martinek A; Nonnast-Daniel B;
    Transplant Proc; 2005 Mar; 37(2):1001-4. PubMed ID: 15848604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
    Vincenti F; Rostaing L;
    Contemp Clin Trials; 2005 Feb; 26(1):17-24. PubMed ID: 15837449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results.
    Krämer BK; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Ortuño J; Sester U; Kunzendorf U; Dietl KH; Bonomini V; Rigotti P; Ronco C; Tabernero JM; Rivero M; Banas B; Mühlbacher F; Arias M; Montagnino G;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2386-92. PubMed ID: 18258740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
    Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
    Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
    Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
    Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients.
    Briggs D; Dudley C; Pattison J; Pfeffer P; Salmela K; Rowe P; Tydén G;
    Transplantation; 2003 Jun; 75(12):2058-63. PubMed ID: 12829912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial.
    Bechstein WO; Malaise J; Saudek F; Land W; Fernandez-Cruz L; Margreiter R; Nakache R; Secchi A; Vanrenterghem Y; Tydén G; Van Ophem D; Berney T; Boucek P; Landgraf R; Kahl A; Squifflet JP;
    Transplantation; 2004 Apr; 77(8):1221-8. PubMed ID: 15114089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period.
    Luan FL; Zhang H; Schaubel DE; Miles CD; Cibrik D; Norman S; Ojo AO
    Am J Transplant; 2008 Sep; 8(9):1871-7. PubMed ID: 18786231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients.
    Silva HT; Yang HC; Abouljoud M; Kuo PC; Wisemandle K; Bhattacharya P; Dhadda S; Holman J; Fitzsimmons W; First MR
    Am J Transplant; 2007 Mar; 7(3):595-608. PubMed ID: 17217442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
    Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
    Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.